263 related articles for article (PubMed ID: 27223432)
1. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options.
Brown RE; Buryanek J; Tammisetti VS; McGuire MF; Csencsits-Smith K
Oncotarget; 2016 Jul; 7(27):41612-41621. PubMed ID: 27223432
[TBL] [Abstract][Full Text] [Related]
2. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
Quesada AE; Nguyen ND; Rios A; Brown RE
Int J Clin Exp Pathol; 2014; 7(12):8732-9. PubMed ID: 25674239
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
4. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
Harada K; Miyake H; Kumano M; Fujisawa M
Br J Cancer; 2013 Oct; 109(9):2389-95. PubMed ID: 24091619
[TBL] [Abstract][Full Text] [Related]
6. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
7. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).
Subbiah V; Brown RE; Jiang Y; Buryanek J; Hayes-Jordan A; Kurzrock R; Anderson PM
PLoS One; 2013; 8(7):e68985. PubMed ID: 23922674
[TBL] [Abstract][Full Text] [Related]
8. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
9. Norcantharidin counteracts acquired everolimus resistance in renal cell carcinoma by dual inhibition of mammalian target of rapamycin complex 1 and complex 2 pathways in Vitro.
Chen X; Cai X; Zheng D; Huang X; Chen Y; Deng T; Mo L; Li H; Li J; Chen S
Anticancer Drugs; 2022 Jan; 33(1):e94-e102. PubMed ID: 34261913
[TBL] [Abstract][Full Text] [Related]
10. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
[TBL] [Abstract][Full Text] [Related]
11. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
12. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways.
Son JY; Yoon S; Tae IH; Park YJ; De U; Jeon Y; Park YJ; Rhyu IJ; Lee BM; Chung KH; Lim JE; Lee SJ; Lee HW; Kwak JH; Kim HS; Choi HY
Cancer Med; 2018 Oct; 7(10):5083-5095. PubMed ID: 30160042
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
15. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
16. PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
Huang B; Fu SJ; Fan WZ; Wang ZH; Chen ZB; Guo SJ; Chen JX; Qiu SP
Cancer Lett; 2016 Jun; 376(1):148-54. PubMed ID: 27037060
[TBL] [Abstract][Full Text] [Related]
17. β-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/ mTOR signalling pathways.
Zhan YH; Liu J; Qu XJ; Hou KZ; Wang KF; Liu YP; Wu B
Asian Pac J Cancer Prev; 2012; 13(6):2739-44. PubMed ID: 22938451
[TBL] [Abstract][Full Text] [Related]
18. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Med Oncol; 2014 Jan; 31(1):792. PubMed ID: 24307346
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
[TBL] [Abstract][Full Text] [Related]
20. Oncogenesis recapitulates embryogenesis via the hypoxia pathway: morphoproteomics and biomedical analytics provide proof of concept and therapeutic options.
Brown RE; McGuire MF
Ann Clin Lab Sci; 2012; 42(3):243-57. PubMed ID: 22964612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
